Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Clinical trial NCT02966353 · COMPLETED

Trial details

NCT number: NCT02966353
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Primary Myelofibrosis Post-Polycythemia Vera-Myelofibrosis Post-Essential Thrombocythemia Myelofibrosis

Start date: 2017-03-31
Primary completion: 2018-07-24
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.